Renfrew Group have been working with UCL and manufacturers as well as patient and clinical groups on the design of a workstation for a highly innovative cryopreservable BioArtificial Liver (UCLBAL) for the treatment of patients with liver failure.
The machine, the first of its kind, will buy time for a patient’s liver to improve or if damage to the liver is irreversible, buy time in providing a “bridge-to-transplant” until liver transplantation can be arranged.
The program which is working toward first ‘in man’ trials, is led by Clare Selden PhD, Professor of Experimental Hepatology of The Liver Group at UCL Medical School, Royal Free Hospital Campus.
Supported by the UCL Translational Research Office, Prof. Selden received a National Institute for Health Research (NIHR) i4i award to fund this research project. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR www.nihr.ac.uk or the Department of Health and Social Care.